yattreblif
2021-10-28
Wow
Merck Projects Billions in Sales of Covid Antiviral Molnupiravir
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
4
6
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":854169852,"tweetId":"854169852","gmtCreate":1635428473107,"gmtModify":1635428513104,"author":{"id":4090156416829480,"idStr":"4090156416829480","authorId":4090156416829480,"authorIdStr":"4090156416829480","name":"yattreblif","avatar":"https://static.tigerbbs.com/0c09ba70f4dad4731020c2b9c484a4da","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":7,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":19,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Wow</p></body></html>","htmlText":"<html><head></head><body><p>Wow</p></body></html>","text":"Wow","highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":4,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/854169852","repostId":1152442963,"repostType":4,"repost":{"id":"1152442963","pubTimestamp":1635427505,"share":"https://www.laohu8.com/m/news/1152442963?lang=&edition=full","pubTime":"2021-10-28 21:25","market":"us","language":"en","title":"Merck Projects Billions in Sales of Covid Antiviral Molnupiravir","url":"https://stock-news.laohu8.com/highlight/detail?id=1152442963","media":"Bloomberg","summary":"(Bloomberg) -- Merck & Co.’s closely watched Covid-19 antiviral molnupiravir could bring in as much ","content":"<p>(Bloomberg) -- Merck & Co.’s closely watched Covid-19 antiviral molnupiravir could bring in as much as $7 billion in global sales through 2022, according to the drugmaker.</p>\n<p>The figure includes up to $1 billion in revenue this year if the experimental drug is authorized in December, Chief Financial Officer Caroline Litchfield said early Thursday on a conference call. She projected at least $5 billion in sales by the end of next year, provided it’s cleared.</p>\n<p>Molnupiravir has become one of the most highly anticipated coronavirus medications, as the pill is relatively cheap to make and easy to transport. Merck has taken steps to make sure that the drug will be distributed widely, including in low-income countries.</p>\n<p>The drugmaker raised its annual forecast as it reported quarterly profit and revenue that beat Wall Street’s expectations. Adjusted earnings for the year will be $5.65 to $5.70 a share, up from the earlier guidance of $5.47 to $5.57, the drugmaker said in a statement. Revenue will be $47.4 billion to $47.9 billion, compared with the earlier guidance that topped out at $47.4 billion. The projections don’t include potential molnupiravir sales.</p>\n<p>Quarterly adjusted earnings were $1.75 a share, beating analysts’ average estimate by 20 cents, according to a statement. Revenue was $13.2 billion, compared with Wall Street expectations of $12.3 billion.</p>\n<p>The shares rose 2% in premarket U.S. trading.</p>\n<p>Merck and partner Ridgeback Biotherapeutics LP are seeking U.S. authorization of molnupiravir, their Covid antiviral. Merck said it plans to make at least 20 million treatment courses of the drug next year, on top of 10 million it expects to make by the end of 2021.</p>\n<p>The drug may become one of Merck’s leading products. Merck’s blockbuster cancer drug Keytruda brought in more than $14 billion in sales last year, followed by the diabetes drug Januvia with around $5 billion and nearly $4 billion for HPV vaccine Gardasil.</p>\n<p>Merck said vaccine revenue contributed to the third-quarter results. However, sales of its pneumococcal vaccine, Pneumovax 23, declined nearly 30%, “primarily driven by lower demand in the United States reflecting prioritization of the Covid-19 vaccine.”</p>\n<p>Sales of the papillomavirus vaccine Gardasil were $1.99 billion, topping estimates. Sales of blockbuster cancer drug Keytruda and the diabetes medications Januvia and Janumet also beat Wall Street projections. Animal health sales were $1.42 billion, in line with expectations.</p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Merck Projects Billions in Sales of Covid Antiviral Molnupiravir</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMerck Projects Billions in Sales of Covid Antiviral Molnupiravir\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-28 21:25 GMT+8 <a href=https://finance.yahoo.com/news/merck-raises-annual-forecast-profit-104849738.html><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Bloomberg) -- Merck & Co.’s closely watched Covid-19 antiviral molnupiravir could bring in as much as $7 billion in global sales through 2022, according to the drugmaker.\nThe figure includes up to $1...</p>\n\n<a href=\"https://finance.yahoo.com/news/merck-raises-annual-forecast-profit-104849738.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRK":"默沙东"},"source_url":"https://finance.yahoo.com/news/merck-raises-annual-forecast-profit-104849738.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1152442963","content_text":"(Bloomberg) -- Merck & Co.’s closely watched Covid-19 antiviral molnupiravir could bring in as much as $7 billion in global sales through 2022, according to the drugmaker.\nThe figure includes up to $1 billion in revenue this year if the experimental drug is authorized in December, Chief Financial Officer Caroline Litchfield said early Thursday on a conference call. She projected at least $5 billion in sales by the end of next year, provided it’s cleared.\nMolnupiravir has become one of the most highly anticipated coronavirus medications, as the pill is relatively cheap to make and easy to transport. Merck has taken steps to make sure that the drug will be distributed widely, including in low-income countries.\nThe drugmaker raised its annual forecast as it reported quarterly profit and revenue that beat Wall Street’s expectations. Adjusted earnings for the year will be $5.65 to $5.70 a share, up from the earlier guidance of $5.47 to $5.57, the drugmaker said in a statement. Revenue will be $47.4 billion to $47.9 billion, compared with the earlier guidance that topped out at $47.4 billion. The projections don’t include potential molnupiravir sales.\nQuarterly adjusted earnings were $1.75 a share, beating analysts’ average estimate by 20 cents, according to a statement. Revenue was $13.2 billion, compared with Wall Street expectations of $12.3 billion.\nThe shares rose 2% in premarket U.S. trading.\nMerck and partner Ridgeback Biotherapeutics LP are seeking U.S. authorization of molnupiravir, their Covid antiviral. Merck said it plans to make at least 20 million treatment courses of the drug next year, on top of 10 million it expects to make by the end of 2021.\nThe drug may become one of Merck’s leading products. Merck’s blockbuster cancer drug Keytruda brought in more than $14 billion in sales last year, followed by the diabetes drug Januvia with around $5 billion and nearly $4 billion for HPV vaccine Gardasil.\nMerck said vaccine revenue contributed to the third-quarter results. However, sales of its pneumococcal vaccine, Pneumovax 23, declined nearly 30%, “primarily driven by lower demand in the United States reflecting prioritization of the Covid-19 vaccine.”\nSales of the papillomavirus vaccine Gardasil were $1.99 billion, topping estimates. Sales of blockbuster cancer drug Keytruda and the diabetes medications Januvia and Janumet also beat Wall Street projections. Animal health sales were $1.42 billion, in line with expectations.","news_type":1},"isVote":1,"tweetType":1,"viewCount":113,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":3,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/854169852"}
精彩评论